Invited Speaker

METABESITY 2021
  • Home
  • About
    • Welcome
    • Target Audience
    • About the Organizers
    • Contact Us
  • Program
    • Program
    • Speakers
    • Program Overview
  • Sponsorship
    • Sponsors
Picture
Gordon Cutler, MD
Formerly Chief, Section on Developmental Endocrinology, NICHD, NIH, and Distinguished Medical Fellow, Eli Lilly & Company, Kinexum Consultant, USA

Dr. Gordon Cutler is a graduate of Harvard College and Harvard Medical School, and completed internship and residency training in internal medicine (at Barnes Hospital) and a fellowship in endocrinology (at the National Institutes of Health). Gordon served as Senior Investigator (1978-1983) and Chief, Section on Developmental Endocrinology (1983-1997), at the National Institute of Child Health and Human Development, and then moved to Lilly Research Laboratories (1997-2008) as Medical Director and later, Distinguished Medical Fellow.
 
Since 2008, he has been an independent consultant to the biotechnology and pharmaceutical industry in the areas of clinical strategy and late-stage clinical trial design and execution. His scientific and professional interests have included disorders of growth, puberty, adrenal and parathyroid gland function, and diabetes. He has published over 290 peer-reviewed papers, and trained numerous adult and pediatric endocrinologists.

Dr. Cutler’s research has led to FDA approval of histrelin (for precocious puberty) and ovine corticorelin (for differential diagnosis of Cushing syndrome), and to new FDA-approved indications for human growth hormone (for idiopathic short stature and SHOX gene deficiency). He led development strategy at Lilly for drugs targeting muscle (e.g., GH, GH secretagogue, SARM, and anti-myostatin), obtained US and EU regulatory advice on treatment of frailty, and co-authored a consensus report on designing RCTs for frailty in the elderly. He also co-invented a novel, ultra-long-acting basal insulin (basal insulin peglispro, LY 2605541)—for which development was halted for business reasons after phase 3 clinical trials—and led the design of 9 phase 3 trials for Lilly’s inhaled insulin product, which was cancelled for commercialization risk.

Gordon is a member of The Endocrine Society, American Diabetes Association, American College of Physicians (Fellow), American Medical Association, and American Association for the Advancement of Science. Honors include the US Public Health Service Commendation Medal, Outstanding Service Medal, and Meritorious Service Medal, and Lilly Research Laboratories President’s Award.
 
​ 
See the Speaker List

Metabesity 2021 Conference Services

Metabesity 2021 c/o The Kitalys Institute
metabesity@gmail.com
Picture
Custom Management Group (CMG)
154 Hansen Road, Suite 201
Charlottesville, VA 22911 USA
cmg@custommanagement.com
​+1 434-971-4788
​
custommanagement.com


Conference  services for Metabesity 2021 are provided by The Kitalys Institute and Custom Management Group. If you need assistance with abstract submission or registration, please contact CMG by e-mail at acockrell@custommanagement.com or by telephone at +1 434-971-4788.
COPYRIGHT METABESITY 2021
  • Home
  • About
    • Welcome
    • Target Audience
    • About the Organizers
    • Contact Us
  • Program
    • Program
    • Speakers
    • Program Overview
  • Sponsorship
    • Sponsors